Results 41 to 50 of about 5,297,540 (313)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study [PDF]

, 2019
Background Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy. Methods Patients with primary triple
Apolone G., Bianchi G. V., Cazzaniga M. E., Colombo M. P., Cosimo S. D., Crippa F., de Braud F., De Santis M. C., Folli S., Generali D., Gulino A., Mariani L., Moretti A., Nicola M. D., Paolini B., Scaperrotta G., Torri V., Tripodo C., Verde N. L.   +18 more
core   +2 more sources

Neoadjuvant therapy for breast cancer [PDF]

, 2019
Objective: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I–III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area.
Carrozzi G., Filiberti R. A., Giorgi Rossi P., Iacovacci S., Mancuso P., Mangone L., Mazzucco W., Minicozzi P., Sant M., Tagliabue G., Tumino R.   +10 more
core   +1 more source

Visual analysis of the research hotspots in neoadjuvant therapy for patients with gastric cancer

Frontiers in Gastroenterology, 2023
ObjectiveThis study aimed to analyze the research hotspots and frontiers in the field of neoadjuvant therapy for patients with gastric cancer (GC) using bibliometric and identify its developmental trends.MethodsThe literature related to neoadjuvant ...
Tianxing Chen, Tianxing Chen, Yating Liu, Yating Liu, Jing Gao, Dekui Zhang, Dekui Zhang   +6 more
doaj   +1 more source

Breast cancer: Monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography [PDF]

, 2003
Background: Aim of the study was to assess the value of scintimammography using Tc-99m sestamibi in the evaluation of tumor response to neoadjuvant chemotherapy.
Brinkbäumer, K., Hahn, K., Keßler, M., Linke, R., Sommer, H., Tiling, R., Untch, M.   +6 more
core   +1 more source

The Role of VEGFA, COX2, HUR and CUGBP2 in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients

Medicina, 2020
Background and objectives: The effectiveness of neoadjuvant therapy, which is commonly used for stage II-III rectal cancer (RC) treatment, is limited. Genes associated with the pathogenesis of RC could determine response to this treatment. Therefore, the
Henrikas Pauzas, Ugne Gyvyte, Tadas Latkauskas, Laura Kairevice, Paulius Lizdenis, Saulius Svagzdys, Erika Birgiolaite, Irma Kuliaviene, Juozas Kupcinskas, Algimantas Tamelis   +9 more
doaj   +1 more source

Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma

Frontiers in Immunology, 2023
PurposeIn patients with resectable esophageal squamous cell carcinoma (ESCC), neoadjuvant therapy increased the curative resection rate, disease-free survival, and overall survival for patients with resectable ESCC.
Xin Nie, Shuya He, Xinming Nie, Changding Li, Kunyi Du, Wenwu He, Zhiyu Li, Kunhan Ni, Simiao Lu, Chenghao Wang, Kangning Wang, Yan Miao, Longlin Jiang, Jiahua Lv, Guangyuan Liu, Qiang Fang, Lin Peng, Wenguang Xiao, Qifeng Wang, Dongsheng Wang, Yongtao Han, Xuefeng Leng   +21 more
doaj   +1 more source

Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keyst

Annals of Translational Medicine, 2022
Background Esophageal squamous cell carcinoma (ESCC) is one of the most refractory malignant tumors. Esophageal cancer (EC) is a malignant tumor with a high incidence worldwide, and over 50% of EC cases occur in China.
X. Shang, Gang Zhao, Fei Liang, Chen Zhang, Weihong Zhang, L. Liu, Runmei Li, X. Duan, Zhao Ma, J. Yue, Chuan-gui Chen, B. Meng, Xiubao Ren, Hongjing Jiang   +13 more
semanticscholar   +1 more source

Preoperative Hormone Therapy in the Treatment of Breast Cancer: What Do We Know So Far?

Креативная хирургия и онкология, 2022
Breast cancer is the most common malignant disease in the world. One of the methods of treating breast cancer is neoadjuvant chemotherapy. Neoadjuvant chemotherapy (NCT) is now the standard of care for locally advanced breast cancer.
V. V. Vorotnikov, R. A. Pakhomova, A. V. Soinov, A. S. Gunina, I. V. Kopytich, M. G. Tsoi, S. A. Abdugafforov   +6 more
doaj   +1 more source

Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives

Journal of Thoracic Oncology, 2023
The standard of care (SoC) for medically operable patients with early-stage (stages I–IIIB) NSCLC is surgery combined with (neo)adjuvant systemic therapy for patients with stages II to IIIB disease and some stage IB or, rarely, chemoradiation (stage III ...
Jay M. Lee, C. Mcnamee, E. Toloza, M. Negrão, Jules Lin, Elaine Shum, A. Cummings, M. Kris, B. Sepesi, I. Bāra, N. Kurtsikidze, K. Schulze, Celina Ngiam, J. Chaft   +13 more
semanticscholar   +1 more source

Comparison of Standard Neoadjuvant Therapy and Total Neoadjuvant Therapy in Terms of Effectiveness in Patients Diagnosed with Locally Advanced Rectal Cancer

Medicina
Background/Objectives: The study aimed to compare the treatment effectiveness of patients with locally advanced rectal cancer undergoing standard neoadjuvant therapy or total neoadjuvant therapy.
Ayberk Bayramgil, Ahmet Bilici, Ali Murat Tatlı, Seda Kahraman, Yunus Emre Altintas, Fahri Akgul, Musa Barış Aykan, Jamshid Hamdard, Sema Sezgin Göksu, Mehmet Ali Nahit Şendur, Fatih Selçukbiricik, Ömer Fatih Ölmez   +11 more
doaj   +1 more source